PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

NCT03449524 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

69

Enrollment

INDUSTRY

Sponsor class

Stopped LOE

Conditions

PAH

Interventions

DRUG: 75mg CXA-10
DRUG: 150mg CXA-10
OTHER: Placebo

Sponsor

Complexa, Inc.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]